Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 3, 2023Blood

DLBCL: who is high risk and how should treatment be optimized?

View Full Paper
Ask AI
Bookmark
Share

Authors

ADAnna Dąbrowska‐IwanickaGNGrzegorz S. Nowakowski

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Dąbrowska‐Iwanicka et al. (2023) studied this question.

synapsesocial.com/papers/6a0ffd02fa36b6e053fd1bd5https://doi.org/10.1182/blood.2023020779
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma2022 · 41 citations
  2. 2Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma2012 · 52 citations
  3. 3Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma2018 · 2,326 citations
  4. 4Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era2010 · 1,643 citations
  5. 5Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies2015 · 409 citations